A combination of IL-2 and IL-18 shielded NK-92MI cells from NKG2D downregulation [159], and an IL-15 super agonist/IL-15Rα rescued tumor cells from immunosuppression [170,171]. This evidence concerns the gene KLRK1 and neoplasm.